Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Nothing Says "Chemistry" Like Nonsense! | Main | An NMR Poster »

December 14, 2011

Now That's A Catalyst

Email This Entry

Posted by Derek

Sorry about the lack of posting today; it's been a busy one. But I do have something that follows up on one of my less useful chemical bulletins, the one the other day about using uranium catalysts. Ben Warner sends along this paper from his time at Los Alamos, and yes, that means what you think it means. You may have done the Meerwein-Pondorf-Verley reaction, but if you have, I'll bet that you wimped out with some laid-back aluminum compound.

But you could have used plutonium, and how does that make you feel? Uranium (III), as it turns out, just doesn't cut it. Accept nothing but plutonium, folks; you can't beat it. And I now return you to your regular research, which I hope has nothing to do with this post at all!

Comments (8) + TrackBacks (0) | Category: Chemical News


COMMENTS

1. Curious Wavefunction on December 14, 2011 1:29 PM writes...

My mind boggles just thinking about the number of organometallic-related Nobel Prizes that will never be awarded because of wimpy concerns about national security. Lack of access to explosive, exotic, intensely radioactive metals will always haunt the organic chemist's conscience.

Permalink to Comment

2. Curious Wavefunction on December 14, 2011 1:33 PM writes...

My mind boggles just thinking about the number of organometallic-related Nobel Prizes that will never be awarded because of wimpy concerns about national security. Lack of access to explosive, exotic, intensely radioactive metals will always haunt the organic chemist's conscience.

Permalink to Comment

3. DrSAR on December 14, 2011 1:42 PM writes...

What isotope would they have used? Pu244 sounds benign but might not be available in useful quantities. I looked at the paper but they don't mention. Is that because it's too obvious or too nat'l-security-sensitive? How am I going to reproduce their experiments if they don't tell me !?

Permalink to Comment

4. RB Woodweird on December 14, 2011 3:09 PM writes...

Too bad 'van Boom's reagent' is already taken.

Permalink to Comment

5. Canageek on December 14, 2011 4:23 PM writes...

I still don't see the problem with the uranium catalyst-- You can easily use depleted uranium, so it would only be marginally more dangerous then lead, and you read about things far more dangerous then lead in the literature all the time. Heck, even natural abundance uranium is safe enough to handle without excessive protection.

Plutonium on the other hand...

It is a shame no one is doing hot-atom chemistry anymore. I found a very interesting book tucked away in our library about using radioactive decomposition in synthetic chemistry. You have to be careful that the bonds holding the radioisotope in place are stronger then the recoil energy, but given that you can make the molecule with one atom, wait a while, and have the molecule suddenly bound to a lighter atom. The downside is it is only practical for very small amounts, and you are limited by the half-life of the isotope; Long enough that you can make the molecule with the mother isotope, short enough you don't have to wait for years to get results.

Permalink to Comment

6. gippgig on December 14, 2011 4:46 PM writes...

Plutonium is unique. The early actinides behave like transition metals; the late ones like rare earths. Plutonium is right on the dividing line, which gives it really weird properties. A good article about this is "Plutonium An element at odds with itself", available at www.fas.org/sgp/othergov/doe/lanl/pubs/00818006.pdf.
I think any isotope would work; chemically they are virtually identical (altho short-lived isotopes do generate a lot of heat & ionizing radiation which can affect reactions).

Permalink to Comment

7. Marty McFly on December 15, 2011 2:28 PM writes...

Plutonium's phase changes are pretty bizarre. Also interesting is that it is warm to the touch, all the time. Even better, if you put a bit in a Delorean and drive 88 miles per hour, you can travel through time and accidentally prevent your parents from ever marrying. Cool stuff. Wish I had some.

Permalink to Comment

8. Tex on January 7, 2012 2:10 PM writes...

There are a few examples of papers I've read which employ the use of plutonium for structural or reactivity studies; in most cases, the papers include some kind of warning or hazard about plutonium. Regarding that, all of the aforementioned warnings have stated that weapons-grade plutonium was employed for those studies, (so most likely a mixture of Pu-239 and Pu-240). I say a mixture because as I'm sure anyone could imagine, the separation of one element from from another isotope of that element can be remarkably difficult. That being said, while I do work with other actinides up to uranium using a very typical organometallic lab, I would DEFINITELY not work with plutonium without having the proper lab and safety equipment installed and ready to go!

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Roger Boisjoly and the Management Hat
Every Methods Paper Has a Table
Buying Back Shares: An Admission of Defeat
More Industrial Espionage
Tau Spreads On Its Own?
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today